Cerebrolysin Spray Canada — Nasal Spray
Porcine Brain Peptide Preparation
Cerebrolysin is a peptide preparation derived from enzymatically processed porcine brain tissue. It consists of a mixture of low molecular weight peptides and free amino acids rather than a single defined molecular entity. This listing is for a spray-format presentation supplied strictly for laboratory research.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Cerebrolysin is a peptide preparation derived from enzymatically processed porcine brain tissue. It consists of a mixture of low molecular weight peptides and free amino acids rather than a single defined molecular entity. This listing is for a spray-format presentation supplied strictly for laboratory research.
In scientific literature, cerebrolysin has been examined in clinical and preclinical investigations relating to acute ischaemic stroke, vascular dementia, traumatic brain injury, and neurodegenerative disease models. Several of these bodies of evidence have been assessed in systematic reviews, which have repeatedly described the underlying trial data as limited in quality.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
Cerebrolysin is characterised in the literature as a heterogeneous peptide preparation, and the published descriptions of its mechanism refer to proposed neurotrophic-like activity rather than a single identified receptor target. Review articles discuss it in the context of neuroprotection and neurorecovery research, though the precise active constituents and the pathways involved are not well established in the published record.
Research endpoints that have been evaluated include mortality and functional outcome scales in acute ischaemic stroke trials, cognitive and global assessment measures in vascular dementia trials, and composite outcome measures following moderate to severe traumatic brain injury. Preclinical work has included nanodelivery formulations examined in Parkinson's disease models. Systematic reviews of the stroke and dementia literature have noted risk of bias, sponsor involvement, and inconsistency across trials, and have characterised the overall certainty of the evidence as low.
Cerebrolysin originated as a brain-derived peptide preparation produced by enzymatic breakdown of porcine brain protein. The specific circumstances and date of its original development are not documented in the available references, and no single originating publication is identified within them.
The research record developed largely through clinical trials conducted in Europe and Asia from the late twentieth century onward, concentrated in acute ischaemic stroke and dementia populations. Successive Cochrane systematic reviews published between 2010 and 2023 reassessed the stroke literature as additional trials appeared, and a parallel series examined the vascular dementia trials. A prospective meta-analysis of a traumatic brain injury trial series was reported in 2021, and preclinical investigation has continued in neurodegeneration models.
Cerebrolysin appears in research frameworks concerned with cerebrovascular injury, cognitive decline, and neurotrauma. Published work includes randomised clinical trials with functional and cognitive outcome endpoints, systematic reviews and meta-analyses evaluating those trials, subgroup analyses in reperfusion-treated stroke populations, and preclinical studies examining delivery formulation in neurodegenerative disease models. Review authors have consistently emphasised methodological limitations in the available trial evidence.
5 of the 5 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Ziganshina 2023, Fiani 2021, Kalinin 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Cui 2019. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Vester 2021, Fiani 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Fiani 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Ozkizilcik 2019. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 6 primary papers published between 2019 and 2024 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Cerebrolysin Spray is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cerebrolysin Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Cerebrolysin Spray is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under acute ischaemic stroke outcome trials, vascular dementia and cognitive assessment research and traumatic brain injury outcome meta-analysis.
The 6 papers cited on this page, published between 2019 and 2024 (2 reviews) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Cerebrolysin Spray is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Cerebrolysin Spray in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
Cerebrolysin Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of cerebrolysin preparation in spray format. Independent third-party analysis verifies identity and net content per batch.
The unit contains only the preparation itself. Any laboratory materials required for handling or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series
PubMedCerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes
PubMedNanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
PubMed[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation]
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
